FOLD Live signaler | Maksimer profitt med Getagraph.com

KJøP 116789 min ago

@ $13.20

Utstedt: 14 feb 2024 @ 21:36

Avkastning: -21.21%

Forrige signal: feb 14 - 15:30

Forrige signal: Selg

Avkastning: 1.62 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 22:00):

Stats
Dagens volum	1.38M
Gjennomsnittsvolum	3.06M
Markedsverdi	3.08B
EPS	$0 ( 2024-02-28 )
Neste inntjeningsdato	( $-0.0600 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-20.39
ATR14	$0.00900 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-01	Campbell Bradley L	Buy	7 500	Common Stock
2024-05-01	Campbell Bradley L	Sell	7 500	Common Stock
2024-05-01	Campbell Bradley L	Sell	7 500	Stock Options (right to buy)
2024-04-15	Prout Samantha	Sell	7 027	Common Stock
2024-04-01	Campbell Bradley L	Buy	7 500	Common Stock

INSIDER POWER
17.19
Last 100 transactions
Buy: 1 721 174 \| Sell: 1 181 964

Volum Korrelasjon

Lang: -0.29 (neutral)

Kort: -0.97 (very strong negative)

Signal:(44.39) Neutral

Amicus Therapeutics Inc Korrelasjon

10 Mest positive korrelasjoner
SHLS	0.913
NVEE	0.903
SHC	0.899
MLCO	0.898
FULC	0.898
ALGT	0.894
SIBN	0.893
ARKO	0.887
MLTX	0.886
LPRO	0.88

10 Mest negative korrelasjoner
HZNP	-0.851
TLMD	-0.848
RXDX	-0.845
KNTK	-0.842
TRMR	-0.838
VITL	-0.837
STAA	-0.837
ENTX	-0.837
AEYE	-0.835
VTVT	-0.834

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Amicus Therapeutics Inc Korrelasjon - Valuta/Råvare

0.62
( weak )

0.51
( weak )

0.00
( neutral )

0.88
( strong )

-0.71
( moderate negative )

Amicus Therapeutics Inc Økonomi

Annual	2023
Omsetning:	$399.36M
Bruttogevinst:	$354.16M (88.68 %)
EPS:	$-0.510

FY	2023
Omsetning:	$399.36M
Bruttogevinst:	$354.16M (88.68 %)
EPS:	$-0.510

FY	2022
Omsetning:	$329.23M
Bruttogevinst:	$290.63M (88.28 %)
EPS:	$-0.820

FY	2021
Omsetning:	$305.51M
Bruttogevinst:	$271.05M (88.72 %)
EPS:	$-0.920

Financial Reports:

No articles found.

Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.

Sanntidsoppdatering for Amicus Therapeutics Inc [FOLD]

Upcoming Earnings Alert